Daniel J Price1,2, Felix Ditzinger3,4, Niklas J Koehl5, Sandra Jankovic3,4, Georgia Tsakiridou6,7, Anita Nair1, René Holm8, Martin Kuentz4, Jennifer B Dressman2, Christoph Saal1. 1. Merck KGaA, Darmstadt, Germany. 2. Frankfurt Goethe University, Frankfurt, Germany. 3. Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland. 4. Institute of Pharma Technology, University of Applied Sciences and Arts Northwestern Switzerland, Muttenz, Switzerland. 5. School of Pharmacy, University College Cork, Cork, Ireland. 6. Pharmathen SA, Product Design & Evaluation, Athens, Greece. 7. Department of Pharmacy, University of Athens, Athens, Greece. 8. Drug Product Development, Janssen Research and Development, Johnson and Johnson, Beerse, Belgium.
Abstract
OBJECTIVES: Supersaturating formulations hold great promise for delivery of poorly soluble active pharmaceutical ingredients (APIs). To profit from supersaturating formulations, precipitation is hindered with precipitation inhibitors (PIs), maintaining drug concentrations for as long as possible. This review provides a brief overview of supersaturation and precipitation, focusing on precipitation inhibition. Trial-and-error PI selection will be examined alongside established PI screening techniques. Primarily, however, this review will focus on recent advances that utilise advanced analytical techniques to increase mechanistic understanding of PI action and systematic PI selection. KEY FINDINGS: Advances in mechanistic understanding have been made possible by the use of analytical tools such as spectroscopy, microscopy and mathematical and molecular modelling, which have been reviewed herein. Using these techniques, PI selection can be guided by molecular rationale. However, more work is required to see widespread application of such an approach for PI selection. SUMMARY: Precipitation inhibitors are becoming increasingly important in enabling formulations. Trial-and-error approaches have seen success thus far. However, it is essential to learn more about the mode of action of PIs if the most optimal formulations are to be realised. Robust analytical tools, and the knowledge of where and how they can be applied, will be essential in this endeavour.
OBJECTIVES: Supersaturating formulations hold great promise for delivery of poorly soluble active pharmaceutical ingredients (APIs). To profit from supersaturating formulations, precipitation is hindered with precipitation inhibitors (PIs), maintaining drug concentrations for as long as possible. This review provides a brief overview of supersaturation and precipitation, focusing on precipitation inhibition. Trial-and-error PI selection will be examined alongside established PI screening techniques. Primarily, however, this review will focus on recent advances that utilise advanced analytical techniques to increase mechanistic understanding of PI action and systematic PI selection. KEY FINDINGS: Advances in mechanistic understanding have been made possible by the use of analytical tools such as spectroscopy, microscopy and mathematical and molecular modelling, which have been reviewed herein. Using these techniques, PI selection can be guided by molecular rationale. However, more work is required to see widespread application of such an approach for PI selection. SUMMARY: Precipitation inhibitors are becoming increasingly important in enabling formulations. Trial-and-error approaches have seen success thus far. However, it is essential to learn more about the mode of action of PIs if the most optimal formulations are to be realised. Robust analytical tools, and the knowledge of where and how they can be applied, will be essential in this endeavour.
Keywords:
controlled and sustained release systems; development of novel analytical techniques; dosage form design and characterisation; pharmaceutical analysis; pharmaceutics and drug delivery
Authors: Felix Ditzinger; Daniel J Price; Anita Nair; Johanna Becker-Baldus; Clemens Glaubitz; Jennifer B Dressman; Christoph Saal; Martin Kuentz Journal: Pharmaceutics Date: 2019-11-04 Impact factor: 6.321
Authors: Deanna M Mudie; Stephanie Buchanan; Aaron M Stewart; Adam Smith; Kimberly B Shepard; Nishant Biswas; Derrick Marshall; Alyssa Ekdahl; Amanda Pluntze; Christopher D Craig; Michael M Morgen; John M Baumann; David T Vodak Journal: Int J Pharm X Date: 2020-02-19